
## Guillermo Villacampa Javierre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9512044/publications.pdf Version: 2024-02-01



Guillermo Villacampa

#	Article	IF	CITATIONS
1	Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. European Radiology, 2021, 31, 1460-1470.	4.5	87
2	Realâ€world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B ell lymphoma. Cancer Medicine, 2021, 10, 3214-3223.	2.8	73
3	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology, 2021, 299, 109-119.	7.3	54
4	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances, 2022, 6, 774-784.	5.2	42
5	Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.9	40
6	Clinical outcome and prognostic factors of patients with Richter syndrome: realâ€world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). British Journal of Haematology, 2020, 190, 854-863.	2.5	36
7	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 2022, 6, 3606-3610.	5.2	35
8	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Annals of Hematology, 2021, 100, 2303-2310.	1.8	32
9	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	7.0	21
10	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2022, 104, 102352.	7.7	17
11	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer, 2020, 132, 53-60.	2.8	16
12	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Frontiers in Oncology, 2021, 11, 638482.	2.8	16
13	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. European Journal of Cancer, 2021, 148, 134-145.	2.8	10
14	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	3.0	10
15	Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Experimental Hematology and Oncology, 2020, 9, 37.	5.0	9
16	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. Npj Breast Cancer, 2021, 7, 73.	5.2	2
17	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia and Lymphoma, 2020, 61, 1823-1832.	1.3	1
18	Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. Leukemia and Lymphoma, 2021, 62, 2288-2291.	1.3	1

#	Article	IF	CITATIONS
19	Patients' and professionals' perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic. Genetics in Medicine, 2021, 23, 1450-1457.	2.4	1
20	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. European Journal of Cancer, 2021, 155, 168-178.	2.8	1
21	Clinical and molecular determinants of treatment benefit with phase I trials in patients (pts) with advanced pancreatic cancer (PC) Journal of Clinical Oncology, 2017, 35, 409-409.	1.6	1